Deal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royalties ADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to ...
SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results